Trade Novartis - CHF - NOVN CFD

Add to favourite

84.95

0.18%

View detailed chart

0.65

Low: 84.9

High: 85.85

Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:20

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.65

Long position overnight fee

-0.015687%

Short position overnight fee

-0.006535%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

CHF

Margin

Stock exchange

Switzerland

Commission on trade

*Information provided by Capital.com

Novartis AG ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	84.8
Open*	85.7
1-Year Change*	2.88%
Day's Range*	84.9 - 85.85
52 wk Range	69.89-90.16
Average Volume (10 days)	2.80M
Average Volume (3 months)	64.62M
Market Cap	195.93B
P/E Ratio	27.61
Shares Outstanding	2.06B
Revenue	42.32B
EPS	3.12
Dividend (Yield %)	3.72093
Beta	0.95
Next Earnings Date	Jan 31, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 1, 2023	84.95	-0.55	-0.64%	85.50	86.10	84.85
Nov 30, 2023	84.80	0.35	0.41%	84.45	84.90	84.00
Nov 29, 2023	84.60	-0.55	-0.65%	85.15	85.70	84.20
Nov 28, 2023	85.15	-0.75	-0.87%	85.90	86.20	84.80
Nov 27, 2023	85.85	-0.50	-0.58%	86.35	86.50	85.75
Nov 24, 2023	86.45	0.35	0.41%	86.10	86.55	85.90
Nov 23, 2023	85.95	0.35	0.41%	85.60	86.00	85.35
Nov 22, 2023	85.80	1.05	1.24%	84.75	86.35	84.75
Nov 21, 2023	84.95	0.80	0.95%	84.15	85.10	83.95
Nov 20, 2023	84.20	0.80	0.96%	83.40	84.30	83.40
Nov 17, 2023	83.95	0.55	0.66%	83.40	84.25	83.05
Nov 16, 2023	82.85	-0.65	-0.78%	83.50	83.90	82.85
Nov 15, 2023	83.40	-0.85	-1.01%	84.25	84.35	82.85
Nov 14, 2023	84.00	-0.80	-0.94%	84.80	85.05	84.00
Nov 13, 2023	84.30	0.35	0.42%	83.95	84.40	83.70
Nov 10, 2023	83.65	-0.80	-0.95%	84.45	84.85	83.25
Nov 9, 2023	84.15	-0.85	-1.00%	85.00	85.00	83.90
Nov 8, 2023	84.65	0.65	0.77%	84.00	85.20	83.65
Nov 7, 2023	83.95	0.05	0.06%	83.90	84.35	83.45
Nov 6, 2023	83.95	0.70	0.84%	83.25	84.05	82.95

Novartis - CHF Events

Time (UTC)	Country	Event
Monday, January 8, 2024
Time (UTC) 10:59	Country CH	Event Novartis AG at JPMorgan Healthcare Conference Novartis AG at JPMorgan Healthcare Conference Forecast - Previous -
Monday, January 29, 2024
Time (UTC) 07:30	Country CH	Event Q4 2023 Novartis AG Earnings Release Q4 2023 Novartis AG Earnings Release Forecast - Previous -
Wednesday, March 6, 2024
Time (UTC) 09:00	Country CH	Event Novartis AG Annual Shareholders Meeting Novartis AG Annual Shareholders Meeting Forecast - Previous -
Monday, April 22, 2024
Time (UTC) 06:30	Country CH	Event Q1 2024 Novartis AG Earnings Release Q1 2024 Novartis AG Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	51742	52877	49898	48624	46017
Revenue	51742	52877	49898	48624	46017
Cost of Revenue, Total	14998	15435	14400	13930	13555
Gross Profit	36744	37442	35498	34694	32462
Total Operating Expense	42545	41188	39746	39538	31824
Selling/General/Admin. Expenses, Total	14190	14815	14093	14319	13690
Research & Development	9088	9041	8484	8386	8154
Depreciation / Amortization	158	109	64	50	179
Unusual Expense (Income)	3402	1173	2503	2284	-4309
Other Operating Expenses, Total	449	653	538	607	549
Operating Income	9197	11689	10152	9086	14193
Interest Income (Expense), Net Non-Operating	-543	14628	-146	-36	-5
Other, Net	-283	-180	-128	-110	-93
Net Income Before Taxes	8371	26137	9878	8940	14095
Net Income After Taxes	6955	24018	8071	7147	12800
Minority Interest	0	3	1	-5	-3
Net Income Before Extra. Items	6955	24021	8072	7142	12797
Net Income	6955	24021	8072	11732	12611
Income Available to Common Excl. Extra. Items	6955	24021	8072	7142	12797
Income Available to Common Incl. Extra. Items	6955	24021	8072	11732	12611
Dilution Adjustment
Diluted Net Income	6955	24021	8072	11732	12611
Diluted Weighted Average Shares	2197	2260	2296	2319	2344
Diluted EPS Excluding Extraordinary Items	3.16568	10.6288	3.51568	3.07978	5.45947
Dividends per Share - Common Stock Primary Issue	3.46171	3.19907	3.38945	3.04815	2.90402
Diluted Normalized EPS	4.47075	11.1183	4.40641	3.86715	3.79006
Total Extraordinary Items				4590	-186
Interest Expense (Income) - Net Operating	260	-38	-336	-38	6

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total revenue	12092	22792	13208	13001	10783
Revenue	12092	22792	13208	13001	10783
Cost of Revenue, Total	3089	5944	3829	3837	2874
Gross Profit	9003	16848	9379	9164	7909
Total Operating Expense	10330	17367	10352	11052	8957
Selling/General/Admin. Expenses, Total	3093	5952	3401	3699	2936
Research & Development	2187	4182	2272	2318	2542
Depreciation / Amortization	169	198	153	42
Interest Expense (Income) - Net Operating	-6	69	46	-28	90
Unusual Expense (Income)	1751	648	298	1145	302
Other Operating Expenses, Total	47	374	353	39	213
Operating Income	1762	5425	2856	1949	1826
Interest Income (Expense), Net Non-Operating	-225	-420	-212	-222	-211
Other, Net	15	189	96	14	-28
Net Income Before Taxes	1552	5194	2740	1741	1587
Net Income After Taxes	1513	4421	2294	1466	1330
Minority Interest	-2	-2	-1	0	-2
Net Income Before Extra. Items	1511	4419	2293	1466	1328
Net Income	1761	4609	2293	1466	1573
Income Available to Common Excl. Extra. Items	1511	4419	2293	1466	1328
Income Available to Common Incl. Extra. Items	1761	4609	2293	1466	1573
Diluted Net Income	1761	4609	2293	1466	1573
Diluted Weighted Average Shares	2075	2086.5	2120	2158	2180
Diluted EPS Excluding Extraordinary Items	0.72819	2.1179	1.0816	0.67933	0.60917
Dividends per Share - Common Stock Primary Issue	0	0	0	3.46171	0
Diluted Normalized EPS	1.55084	2.38225	1.20956	1.14055	0.72527
Total Extraordinary Items	250	190			245

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	36910	45718	29673	29504	35563
Cash and Short Term Investments	18726	28113	11293	11234	15718
Cash	2877	3396	3750	3247	3121
Cash & Equivalents	4640	9011	5908	7865	10150
Short Term Investments	11209	15706	1635	122	2447
Total Receivables, Net	9894	9621	10036	10337	11036
Accounts Receivable - Trade, Net	8066	8005	8217	8301	8739
Total Inventory	7175	6666	7131	5982	6956
Prepaid Expenses	911	1102	943	898	812
Other Current Assets, Total	204	216	270	1053	1041
Total Assets	117453	131795	127778	118370	145563
Property/Plant/Equipment, Total - Net	12195	13106	13939	13746	15696
Property/Plant/Equipment, Total - Gross	26304	28708	29894	28676	34028
Accumulated Depreciation, Total	-14109	-15602	-15955	-14930	-18332
Goodwill, Net	29301	29595	29999	26524	35294
Intangibles, Net	31644	34182	36809	28787	38719
Long Term Investments	1606	2268	11611	10538	9789
Note Receivable - Long Term	948	973	922	624	908
Other Long Term Assets, Total	4849	5953	4825	8647	9594
Total Current Liabilities	28656	30208	33059	28264	29607
Accounts Payable	5146	5553	5403	5424	5556
Accrued Expenses	5334	5100	5336	5058	5105
Notes Payable/Short Term Debt	3635	3606	7319	4844	6430
Current Port. of LT Debt/Capital Leases	2492	2896	2558	2248	3190
Other Current Liabilities, Total	12049	13053	12443	10690	9326
Total Liabilities	58111	64140	71180	62896	66949
Total Long Term Debt	21782	24523	27978	22056	22470
Long Term Debt	20244	22902	26259	20353	22470
Deferred Income Tax	2686	3070	3141	5867	7475
Minority Interest	81	167	68	77	78
Other Liabilities, Total	4906	6172	6934	6632	7319
Total Equity	59342	67655	56598	55474	78614
Common Stock	890	901	913	936	944
Retained Earnings (Accumulated Deficit)	63540	70989	57157	59274	82191
Treasury Stock - Common	-92	-48	-53	-80	-69
Unrealized Gain (Loss)	-198				206
Other Equity, Total	-4798	-4187	-1419	-4656	-4658
Total Liabilities & Shareholders’ Equity	117453	131795	127778	118370	145563
Total Common Shares Outstanding	2119.61	2234.94	2256.82	2265.01	2311.17
Capital Lease Obligations	1538	1621	1719	1703

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	45660	33493	32114	36910	36954
Cash and Short Term Investments	12695	11174	12260	18930	19103
Cash & Equivalents	12405	10885	12000	7517	8726
Short Term Investments	290	289	260	11413	10377
Total Receivables, Net	7099	9543	9183	8334	8680
Accounts Receivable - Trade, Net	6819	9195	8916	8066	8422
Total Inventory	5610	8228	7886	7175	6779
Other Current Assets, Total	20256	4548	2785	2471	2392
Total Assets	112697	110979	112241	117453	118464
Property/Plant/Equipment, Total - Net	10344	12277	12348	12195	11731
Goodwill, Net	23416	29522	29481	29301	28668
Intangibles, Net	26418	28003	30451	31644	31888
Long Term Investments	2122	2433	2555	2554	2491
Other Long Term Assets, Total	4737	5251	5292	4849	6732
Total Current Liabilities	48393	31909	30549	28656	28160
Accounts Payable	3870	5350	5426	5146	4693
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	5602	8496	7166	6127	7204
Other Current Liabilities, Total	38921	18063	17957	17383	16263
Total Liabilities	74533	59132	60182	58111	57644
Total Long Term Debt	19521	19804	21985	21782	21235
Long Term Debt	18068	18259	20396	20244	19732
Capital Lease Obligations	1453	1545	1589	1538	1503
Deferred Income Tax	2457	2526	2727	2686	2719
Minority Interest	81	84	83	81	78
Other Liabilities, Total	4081	4809	4838	4906	5452
Total Equity	38164	51847	52059	59342	60820
Common Stock	825	842	842	890	890
Retained Earnings (Accumulated Deficit)	37371	51057	51253	58544	60000
Treasury Stock - Common	-32	-52	-36	-92	-70
Total Liabilities & Shareholders’ Equity	112697	110979	112241	117453	118464
Total Common Shares Outstanding	2055.46	2068.26	2097.4	2119.61	2150.98

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	6955	24018	8071	7147	12800
Cash From Operating Activities	14236	15071	13650	13625	14272
Cash From Operating Activities	1873	1807	2088	1852	1783
Amortization	5308	4306	4376	3974	3428
Non-Cash Items	4404	-11714	3842	3369	-2315
Cash Taxes Paid	1975	2342	1833	1876	1506
Cash Interest Paid	696	664	703	793	816
Changes in Working Capital	-4304	-3346	-4727	-2717	-1424
Cash From Investing Activities	1468	4208	-13182	-2226	-5591
Capital Expenditures	-2671	-2971	-2585	-2257	-2648
Other Investing Cash Flow Items, Total	4139	7179	-10597	31	-2943
Cash From Financing Activities	-20562	-16264	-2208	-13627	-4244
Financing Cash Flow Items	55	94	-199	3307	-119
Total Cash Dividends Paid	-7506	-7368	-6987	-6645	-6966
Issuance (Retirement) of Stock, Net	-10552	-3004	-2094	-5332	-1336
Issuance (Retirement) of Debt, Net	-2559	-5986	7072	-4957	4177
Foreign Exchange Effects	-32	-266	286	69	-26
Net Change in Cash	-4890	2749	-1454	-2159	4411

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	2294	6955	5489	3914	2219
Cash From Operating Activities	2957	14236	10125	5404	1649
Cash From Operating Activities	377	7181	5233	3207	1405
Amortization	1619
Non-Cash Items	1085	4404	3417	2164	918
Cash Taxes Paid	348	1975	1559	1239	633
Cash Interest Paid	123	696	475	308	110
Changes in Working Capital	-2418	-4304	-4014	-3881	-2893
Cash From Investing Activities	10621	1468	2935	-2263	9365
Capital Expenditures	-470	-2671	-2024	-1442	-859
Other Investing Cash Flow Items, Total	11091	4139	4959	-821	10224
Cash From Financing Activities	-9202	-20562	-16568	-11830	-9528
Financing Cash Flow Items	-169	55	99	97	22
Total Cash Dividends Paid	-7255	-7506	-7506	-7506	-7506
Issuance (Retirement) of Stock, Net	-2727	-10552	-7874	-5156	-2448
Issuance (Retirement) of Debt, Net	949	-2559	-1287	735	404
Foreign Exchange Effects	107	-32	-173	-93	-41
Net Change in Cash	4483	-4890	-3681	-8782	1445

Investor Name	Investor Type	Percent Outstanding	Shares Held	Shares change	Holdings Date	Turnover Rating
BlackRock Institutional Trust Company, N.A.	Investment Advisor	5.3489	121820582	0	2022-12-31	LOW
Sandoz Family	Other Insider Investor	3.9262	89417347	281387	2023-10-04	LOW
The Vanguard Group, Inc.	Investment Advisor/Hedge Fund	2.7895	63531133	1299090	2023-09-30	LOW
UBS Asset Management (Switzerland)	Investment Advisor	2.4548	55906821	176139	2022-12-31	LOW
Norges Bank Investment Management (NBIM)	Sovereign Wealth Fund	2.3806	54217976	0	2022-12-31	LOW
Credit Suisse Funds AG	Investment Advisor/Hedge Fund	2.1663	49335879	-677105	2022-12-31	LOW
Wellington Management Company, LLP	Investment Advisor/Hedge Fund	1.9169	43657691	-98523	2023-09-30	LOW
Zürcher Kantonalbank (Asset Management)	Bank and Trust	1.1699	26643704	-83783	2023-09-30	LOW
BlackRock Advisors (UK) Limited	Investment Advisor/Hedge Fund	0.9161	20863639	608108	2023-09-30	LOW
Artisan Partners Limited Partnership	Investment Advisor	0.7657	17438508	97459	2023-09-30	LOW
Dodge & Cox	Investment Advisor/Hedge Fund	0.7442	16949270	-57400	2023-09-30	LOW
Geode Capital Management, L.L.C.	Investment Advisor/Hedge Fund	0.5744	13081380	2934	2023-09-30	LOW
Capital Research Global Investors	Investment Advisor	0.5466	12449633	-629519	2023-09-30	LOW
DWS Investment GmbH	Investment Advisor/Hedge Fund	0.5435	12377422	38670	2023-09-30	LOW
Pictet Asset Management Ltd.	Investment Advisor/Hedge Fund	0.5245	11946070	-138667	2023-06-30	LOW
California Public Employees' Retirement System	Pension Fund	0.5222	11892523	2527466	2022-06-30	LOW
BlackRock Investment Management (UK) Ltd.	Investment Advisor/Hedge Fund	0.4086	9305832	96874	2023-08-31	LOW
MFS Investment Management	Investment Advisor/Hedge Fund	0.374	8518108	259838	2023-09-30	LOW
Nuveen LLC	Pension Fund	0.3733	8500770	-43383	2023-09-30	LOW
Fidelity International	Investment Advisor	0.272	6195340	-13114	2023-09-30	LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Novartis - CHF Company profile

Novartis AG (NVS) is a global pharmaceutical company. Founded in 1996 through a merger of Ciba-Geigy and Sandoz, Novartis is headquartered in Basel, Switzerland. The firm has two divisions: Innovative Medicines and Sandoz.

Innovative Medicines offer prescription medicines and create treatments in areas of respiratory, ophthalmology, neuroscience, immunology, hepatology, dermatology, cardiovascular, renal and metabolism.

Sandoz develops, manufactures and markets generic pharmaceuticals and biosimilars. Sandoz products include: Adakveo (crizanlizumab), Afinitor Disperz/Votubia (everolimus) and Arzerra (ofatumumab) for Oncology; and Aimovig (erenumab) for neuroscience.

In 2020, in response to the pandemic, the company collaborated with Molecular Partners to develop ensovibep, a DARPin therapeutic candidate designed for potential use against Covid-19.

The company’s shares have been listed on the New York Stock Exchange (NYSE) since 2000. Novartis AG stock is traded under the ticker symbol NVS. You can track live NVS share value and price history at Capital.com.

Industry:

Pharmaceuticals (NEC)

Lichtstrasse 35
BASEL
BASEL-STADT 4056
CH

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023